A Review of Immune Modulators and Immunotherapy in Infectious Diseases

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2023 Sep 8

PMID 37682390

Authors

P Sangeetha Vijayan

Joseph Xavier

Mohanan Parayanthala Valappil

Affiliations

Soon will be listed here.

Abstract

The human immune system responds to harmful foreign invaders frequently encountered by the body and employs defense mechanisms to counteract such assaults. Various exogenous and endogenous factors play a prominent role in maintaining the balanced functioning of the immune system, which can result in immune suppression or immune stimulation. With the advent of different immune-modulatory agents, immune responses can be modulated or regulated to control infections and other health effects. Literature provides evidence on various immunomodulators from different sources and their role in modulating immune responses. Due to the limited efficacy of current drugs and the rise in drug resistance, there is a growing need for new therapies for infectious diseases. In this review, we aim to provide a comprehensive overview of different immune-modulating agents and immune therapies specifically focused on viral infectious diseases.

Citing Articles

Plant-Derived as Alternatives to Animal-Derived Bioactive Peptides: A Review of the Preparation, Bioactivities, Structure-Activity Relationships, and Applications in Chronic Diseases.

Sun L, Liu J, He Z, Du R Nutrients. 2024; 16(19).

PMID: 39408244 PMC: 11479132. DOI: 10.3390/nu16193277.

Vitamin K: Infection, Inflammation, and Auto-Immunity.

Xie Y, Li S, Wu D, Wang Y, Chen J, Duan L J Inflamm Res. 2024; 17:1147-1160.

PMID: 38406326 PMC: 10893789. DOI: 10.2147/JIR.S445806.

References

Vesely M, Kershaw M, Schreiber R, Smyth M . Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011; 29:235-71. DOI: 10.1146/annurev-immunol-031210-101324. View

Florez-Sampedro L, Song S, Melgert B . The diversity of myeloid immune cells shaping wound repair and fibrosis in the lung. Regeneration (Oxf). 2018; 5(1):3-25. PMC: 5911451. DOI: 10.1002/reg2.97. View

Puri A, Saxena R, Saxena R, Saxena K, Srivastava V, Tandon J . Immunostimulant activity of Nyctanthes arbor-tristis L. J Ethnopharmacol. 1994; 42(1):31-7. DOI: 10.1016/0378-8741(94)90020-5. View

Wen C, Chen H, Yang N . Developing Phytocompounds from Medicinal Plants as Immunomodulators. Adv Bot Res. 2020; 62:197-272. PMC: 7150268. DOI: 10.1016/B978-0-12-394591-4.00004-0. View

Germain R . Vaccines and the future of human immunology. Immunity. 2010; 33(4):441-50. DOI: 10.1016/j.immuni.2010.09.014. View

Coffman R, Sher A, Seder R . Vaccine adjuvants: putting innate immunity to work. Immunity. 2010; 33(4):492-503. PMC: 3420356. DOI: 10.1016/j.immuni.2010.10.002. View

Di Pasquale A, Preiss S, Da Silva F, Garcon N . Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel). 2015; 3(2):320-43. PMC: 4494348. DOI: 10.3390/vaccines3020320. View

Nicholls E, Madera L, Hancock R . Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Ann N Y Acad Sci. 2010; 1213:46-61. DOI: 10.1111/j.1749-6632.2010.05787.x. View

Ghimire T, Benson R, Garside P, Brewer J . Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. Immunol Lett. 2012; 147(1-2):55-62. PMC: 3477319. DOI: 10.1016/j.imlet.2012.06.002. View

10.

Marrack P, McKee A, Munks M . Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009; 9(4):287-93. PMC: 3147301. DOI: 10.1038/nri2510. View

11.

Grun J, Maurer P . Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol. 1989; 121(1):134-45. DOI: 10.1016/0008-8749(89)90011-7. View

12.

Metcalf D . The colony-stimulating factors and cancer. Cancer Immunol Res. 2014; 1(6):351-6. PMC: 3918448. DOI: 10.1158/2326-6066.CIR-13-0151. View

13.

Chuang Y, He L, Pinn M, Tsai Y, Cheng M, Farmer E . Albumin fusion with granulocyte-macrophage colony-stimulating factor acts as an immunotherapy against chronic tuberculosis. Cell Mol Immunol. 2020; 18(10):2393-2401. PMC: 8484439. DOI: 10.1038/s41423-020-0439-2. View

14.

OHagan D, Ott G, De Gregorio E, Seubert A . The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine. 2012; 30(29):4341-8. DOI: 10.1016/j.vaccine.2011.09.061. View

15.

OHagan D, Friedland L, Hanon E, Didierlaurent A . Towards an evidence based approach for the development of adjuvanted vaccines. Curr Opin Immunol. 2017; 47:93-102. DOI: 10.1016/j.coi.2017.07.010. View

16.

Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M . Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A. 2009; 106(19):7962-7. PMC: 2674105. DOI: 10.1073/pnas.0903181106. View

17.

OHagan D, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G . MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines. 2011; 10(4):447-62. DOI: 10.1586/erv.11.23. View

18.

Ko E, Kang S . Immunology and efficacy of MF59-adjuvanted vaccines. Hum Vaccin Immunother. 2018; 14(12):3041-3045. PMC: 6343625. DOI: 10.1080/21645515.2018.1495301. View

19.

Kayraklioglu N, Horuluoglu B, Klinman D . CpG Oligonucleotides as Vaccine Adjuvants. Methods Mol Biol. 2020; 2197:51-85. DOI: 10.1007/978-1-0716-0872-2_4. View

20.

Shirota H, Klinman D . Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev Vaccines. 2013; 13(2):299-312. PMC: 6335645. DOI: 10.1586/14760584.2014.863715. View